HC Wainwright Reiterates “Buy” Rating for ASLAN Pharmaceuticals (NASDAQ:ASLN)

HC Wainwright restated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a report issued on Tuesday, Benzinga reports. They currently have a $9.00 price target on the stock.

Separately, Piper Sandler reiterated an overweight rating and set a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Price Performance

ASLN opened at $0.42 on Tuesday. The company has a fifty day moving average price of $0.60 and a 200-day moving average price of $0.72. ASLAN Pharmaceuticals has a one year low of $0.39 and a one year high of $4.69. The firm has a market capitalization of $6.79 million, a P/E ratio of -0.15 and a beta of 1.45.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last released its quarterly earnings results on Friday, April 12th. The company reported ($0.78) EPS for the quarter. On average, analysts expect that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.